Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05311618 · ClinicalTrials.gov registry record · Phase 1

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

A Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by NGM Biopharmaceuticals.

Active
Registry status
Phase 1
Development phase
71
Enrollment target
6
Study locations

NCT05311618 is a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer that is active but no longer recruiting, run by NGM Biopharmaceuticals. The registered enrollment target is 71 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05311618, a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by NGM Biopharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
71 participants
Enrollment target
6
Study locations

Study Summary

Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors

Conditions Studied

Breast Cancer Non-Small Cell Lung Cancer Colorectal Cancer Pancreatic Cancer Gastric Cancer Cervical Cancer Esophageal Cancer Squamous Cell Carcinoma of Head and Neck Endocervical Cancer Bladder Urothelial Cancer

Interventions

  • DRUG Pembrolizumab (KEYTRUDA ®)
  • DRUG NGM438

Study Locations (6)

Michigan

  • Henry Ford Health System - Detroit
  • START Midwest - Grand Rapids

Colorado

  • SCRI Denver - Denver

Connecticut

  • Yale Cancer Center - New Haven

New York

  • Mount Sinai Hospital - New York

Texas

  • MD Anderson - Houston

Trial Details

FieldValue
Enrollment Target 71 participants
Start Date 2022-05-11
Est. Completion 2025-06
Phase Phase 1

Sponsor

NGM Biopharmaceuticals

18 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05311618

The ClinicalTrials.gov registry entry for NCT05311618 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is NGM Biopharmaceuticals, which has 18 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab (KEYTRUDA ®) is the first listed.

NCT05311618 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Michigan, Colorado, Connecticut.

Frequently Asked Questions

What is clinical trial NCT05311618 about?

NCT05311618 is a clinical study titled "Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors". Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors

What is the current status of trial NCT05311618?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2022-05-11. Estimated completion is 2025-06.

What conditions does trial NCT05311618 study?

This clinical trial studies the following conditions: Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Gastric Cancer.

What interventions are being tested in trial NCT05311618?

The interventions under investigation include: Pembrolizumab (KEYTRUDA ®) (DRUG), NGM438 (DRUG).

Who is sponsoring clinical trial NCT05311618?

This trial is sponsored by NGM Biopharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05311618 being conducted?

This trial has 6 study locations across Colorado, Connecticut, Michigan, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Non-Small Cell Lung Cancer

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.